564 related articles for article (PubMed ID: 28039357)
1. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
[TBL] [Abstract][Full Text] [Related]
4. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
[TBL] [Abstract][Full Text] [Related]
6. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
7. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
[TBL] [Abstract][Full Text] [Related]
8. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
9. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
12. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
13. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
14. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
Rice SJ; Liu X; Wang HG; Belani CP
PLoS One; 2019; 14(5):e0217657. PubMed ID: 31150457
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
17. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
18. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
19. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
20. BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.
Korfi K; Smith M; Swan J; Somervaille TC; Dhomen N; Marais R
Cell Death Dis; 2016 Apr; 7(4):e2177. PubMed ID: 27054332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
